<DOC>
	<DOCNO>NCT02692755</DOCNO>
	<brief_summary>This study aim evaluate hematological safety palbociclib letrozole African American woman hormone receptor positive HER2 negative advance breast cancer . Hematological safety composite endpoint episode febrile neutropenia treatment discontinuation due neutropenia accord current recommendation management neutropenia</brief_summary>
	<brief_title>Palbociclib / Letrozole African American Women With HR+ HER2- Breast Cancer</brief_title>
	<detailed_description>The study design assess rate completion plan oncology therapy absence hematological event define episode febrile neutropenia treatment discontinuation due neutropenia . A completion rate 80 % consider clinical relevance benefit breast cancer patient high risk ethnic neutropenia completion rate 60 % consider poor justify additional safety study . A two stage design total 35 patient used test completion rate least 80 % versus 60 % 80 % power significance level 5 % . An exact confidence interval completion rate calculate . Investigators estimate 10 % rate febrile neutropenia . Due small sample size , analysis secondary endpoint descriptive include specific hypothesis testing .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Selfidentified Black , African African American woman ≥ 18 year age proven diagnosis advance adenocarcinoma breast ( locoregionally recurrent metastatic disease ) 2 . ERpositive and/or PgRpositive tumor base local laboratory result 3 . HER2negative breast cancer base local laboratory result ( test use per local practice ) 4 . Patients must appropriate candidate letrozole therapy 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 6 . Adequate bone marrow function : Absolute Neutrophil Count ( ANC ) ≥ 1,000/mm3 ( 1.0 x 109/L ) ; Platelets ≥100,000/mm3 ( 100 x 109/L ) ; Hemoglobin ≥9 g/dL ( 90 g/L ) . 1 . Current use food drug know potent inhibitor inducer CYP3A4 2 . Active uncontrolled symptomatic brain metastasis . Previously treat clinically stable , per Investigator 's judgment , brain metastasis permit . 3 . Previous CDK4/6 inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>African American</keyword>
</DOC>